Alligator Bioscience receives patent approval for the drug candidate ATOR-1015
Alligator Bioscience announced the issuance of U.S. Patent No. 10,774,150 for its bispecific drug candidate, ATOR-1015, which targets CTLA-4 for metastatic cancer treatment. The patent protects this innovation until at least 2036, addressing challenges in immuno-oncology. Safety data from the ongoing Phase I clinical study were presented at ASCO in June 2020, with the study expected to conclude in Q4 2020 and a Phase Ib study planned for 2021.
- Patent protection for ATOR-1015 extends until at least 2036, securing intellectual property.
- Promising safety data from ATOR-1015's Phase I clinical study presented at ASCO.
- Ongoing development of ATOR-1015 aims to address a major challenge in cancer treatment.
- None.
LUND, Sweden, Sept. 16, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,774,150 which covers compositions of matter directed to Alligator's bispecific drug candidate ATOR-1015. The granted patent's earliest expiry year is 2036.
"ATOR-1015 constitutes a new concept, a tumor-localizing bispecific CTLA-4 antibody. Our invention addresses one of the key challenges within immuno-oncology, i.e. the narrow therapeutic window of CTLA-4 drugs. This is now protected by a granted US patent," commented Per Norlén, CEO at Alligator Bioscience.
ATOR-1015 is developed for the treatment of metastatic cancer. Promising safety data from the ongoing ATOR-1015 Phase I clinical study was presented at ASCO in June 2020. The Phase I dose escalation study is planned to be completed during the fourth quarter 2020 and the subsequent Phase Ib efficacy study in malignant melanoma is due to start in 2021.
For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on September 16, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes five lead clinical and preclinical drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Alligator Bioscience receives patent approval for the drug candidate ATOR-1015 |
View original content:http://www.prnewswire.com/news-releases/alligator-bioscience-receives-patent-approval-for-the-drug-candidate-ator-1015-301131985.html
SOURCE Alligator Bioscience
FAQ
What is the significance of the patent issued for ATOR-1015 by Alligator Bioscience?
When is the Phase I clinical study for ATOR-1015 expected to conclude?
What is the purpose of ATOR-1015 in cancer treatment?
What were the findings from the ASCO presentation about ATOR-1015?
What is the timeline for the Phase Ib efficacy study for ATOR-1015?
